Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin Lymphoma

Chimeric antigen receptor T cells (CAR-T cell) targeting CD19 are effective against several subtypes of CD19-expressing hematologic malignancies. Centralized manufacturing has allowed rapid expansion of this cellular therapy, but it may be associated with treatment delays due to the required logisti...

Full description

Bibliographic Details
Main Authors: Zachary Jackson, Anne Roe, Ashish Arunkumar Sharma, Filipa Blasco Tavares Pereira Lopes, Aarthi Talla, Sarah Kleinsorge-Block, Kayla Zamborsky, Jennifer Schiavone, Shivaprasad Manjappa, Robert Schauner, Grace Lee, Ruifu Liu, Paolo F. Caimi, Ying Xiong, Winfried Krueger, Andrew Worden, Mike Kadan, Dina Schneider, Rimas Orentas, Boro Dropulic, Rafick-Pierre Sekaly, Marcos de Lima, David N. Wald, Jane S. Reese
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Immunology
Subjects:
automated
CAR-T
manufacturing
Prodigy
stem cell memory T
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01941/full

Similar Items

Similar Items